How would you incorporate results from the PRESTO trial into your practice in light of greater use of PSMA PET scans for prostate cancer?
Would you consider the PRESTO regimen of ADT+Apalutamide for 52 weeks for patients with PSMA PET+ disease with negative conventional scans?